Bevacizumab Treatment and Retinal Vessel Monitoring
- Registration Number
- NCT00740168
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
Bevacizumab might influence the dynamic vessel function after being administered intravenously.
- Detailed Description
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- patients who wish and need bevacizumab treatment for underlying disease
Exclusion Criteria
- previous bevacizumab treatment
- known eye disease, eye surgery or eye trauma in history
- myopia >-2.0 dpt
- hyperopia > +2.0 dpt.
- relevant media opacity of the lens
- acute heart disease, ischemic insult, proven coronary heart disease
- cardiac arrhythmia or vessel anomalies
- seizure disorder or episode in history
- migraine
- treatment with corticosteroids within 4 weeks before study inclusion
- intake of vasoactive drugs like AT-1 or glitazone
- pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description TG bevacizumab treatment Bevacizumab treatment group with metastasized cancer
- Primary Outcome Measures
Name Time Method Diameter of retinal vessels and dynamic vessel reaction Measurements before and after administration
- Secondary Outcome Measures
Name Time Method Baroreflex sensitivity, heart frequence variability, reaction to handgrip test Measurements before and after administration
Trial Locations
- Locations (1)
Autonomic lab (ANF)
🇩🇪Dresden, Sachsen, Germany